Market Report, "EpiCast Report: Acute Myeloid Leukemia - Epidemiology Forecast to 2022", Published

Boston, MA -- (SBWire) -- 07/13/2013 --Acute myeloid leukemia (AML) is a rare cancer that accounts for a disproportionally high number of cancer-related deaths (O'Donnell et al., 2012; RKI, 2012). The disease is more common in the elderly and is slightly more common in men than in women (ACS, 2013; O'Donnell et al., 2012). AML progresses quickly and has low survival and high rates of relapse even with treatment (ACS, 2013; ASCO, 2012; O'Donnell et al., 2012). The age of the patient, specifically over or under 60 years of age, and the classification of the disease are important factors that determine the treatment plan (NCI, 2013; Shah et al., 2013).

GlobalData epidemiologists forecast that the 6MM had 23,497 incident cases of AML in 2012, and close to half of the incident cases occurred in the US. The 6MM will experience an increase in disease burden driven by population increase in the next 10 years at the rate of 1.80% per year, resulting in 27,717 incident cases in 2022. The growth of incident cases in the US is the highest amongst all markets at 2.29% per year, whereas the 5EU (France, Germany, Italy, Spain, and the UK) has a slightly slower growth rate of 1.33% per year from 2012-2022.

View Full Report Details and Table of Contents

Scope

- The acute myeloid leukemia (AML) EpiCast Report provides an overview of the risk factors and the global and historical epidemiological trends for AML in the six major markets (6MM): the US, France, Germany, Italy, Spain, and the UK. In addition, the report also includes a 10-year forecast of the following segmentations in adults aged 20 and older across the 6MM.
- Incident cases of AML segmented by sex and 10-year age groups
- Five-year prevalent cases of AML segmented by the age groups 20-59 years and ending at ages 60 years and older
- Incident and five-year prevalent cases of acute promyelocytic leukemia (APL) and myelodysplastic syndromes/therapy-related acute myeloid leukemia (MDS/therapy-related AML) segmented by the age groups 20-59 years and ending at ages 60 years and older
- Incident cases of AML with mutations in the FLT3 gene
- Incident cases of AML classified in favorable, intermediate, and adverse risk groups

Reasons to Get This Report

- Develop business strategies by understanding the trends shaping and driving the global AML market.
- Quantify patient populations in the global AML market to improve product development, pricing, and launch plans.
- Organize sales and marketing efforts by identifying sex, age groups, subtypes, and risk groups that present the best opportunities for AML therapeutics in each of the markets covered.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022
- EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2022
- EpiCast Report: Pediatric Respiratory Syncytial Virus Infection and Prophylactic Populations in the US - Epidemiology Forecast to 2022
- EpiCast Report: Psoriasis - Epidemiology Forecast to 2022
- EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
- EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022
- EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022
- EpiCast Report: Dermatophytic Onychomycosis - Epidemiology Forecast to 2022
- EpiCast Report: Human Immunodeficiency Virus - Epidemiology Forecast to 2022
- EpiCast Report: Idiopathic Pulmonary Fibrosis - Epidemiology Forecast to 2022